Therapeutic oligonucleotides: the road not taken.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 21862637.
- Also identified by DOI 10.1158/1078-0432.CCR-11-2013.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Antisense oligonucleotide therapeutics have been in development for almost 25 years without a single U.S. Food and Drug Administration-approved product in cancer. The reasons for this absence stem, in part, from a deep lack of understanding about how to deliver these molecules to cancer cells in vivo.
Medical subject headings
- Antineoplastic Agents
- DNA-Binding Proteins
- Oligonucleotides
- Oligonucleotides, Antisense
- Transcription Factors